Structure Therapeutics (NASDAQ:GPCR) Stock Falls 6.1% – Here’s What Happened

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) shares dropped 6.1% during mid-day trading on Tuesday. The company traded as low as $33.04 and last traded at $32.9330. Approximately 497,334 shares were traded during trading, a decline of 46% from the average session volume of 920,710 shares. The stock had previously closed at $35.06.

Analysts Set New Price Targets

A number of analysts recently weighed in on GPCR shares. Citigroup restated a “market outperform” rating on shares of Structure Therapeutics in a research report on Friday, August 7th. Canaccord Genuity Group set a $111.00 target price on Structure Therapeutics in a report on Friday, August 7th. Citizens Jmp reiterated a “market outperform” rating and set a $110.00 target price on shares of Structure Therapeutics in a report on Wednesday, September 9th. HC Wainwright reiterated a “buy” rating on shares of Structure Therapeutics in a report on Wednesday, September 9th. Finally, Wall Street Zen upgraded shares of Structure Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, August 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $110.91.

Structure Therapeutics Price Performance

The business has a 50-day moving average of $46.25 and a 200 day moving average of $46.43. The company has a market cap of $2.29 billion, a PE ratio of -32.83 and a beta of -1.45.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, equities analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.87 EPS for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Sterling Capital Management LLC purchased a new position in Structure Therapeutics during the 1st quarter valued at approximately $28,000. IFP Advisors Inc bought a new position in Structure Therapeutics during the 2nd quarter valued at about $46,000. Assetmark Inc. raised its position in Structure Therapeutics by 21.4% in the 1st quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock worth $123,000 after purchasing an additional 449 shares during the period. ProShare Advisors LLC purchased a new position in shares of Structure Therapeutics during the fourth quarter valued at approximately $206,000. Finally, Janney Montgomery Scott LLC purchased a new position in Structure Therapeutics during the 1st quarter valued at $329,000. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing oral medicines for chronic diseases. The company uses its structure-based drug discovery platform to target G protein-coupled receptors (GPCRs), a large class of proteins involved in metabolic, cardiovascular and pulmonary functions.

Its lead program is GSBR-1290, also known as aleniglipron, an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist being developed for conditions including obesity and type 2 diabetes.